Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The June 1999 Formulary monographs are on levalbuterol inhalation solution, itraconazole injection, amprenavir, pioglitazone, and cytarabine liposome injection. The DUE is on itraconazole injection.
Get full access to this article
View all access options for this article.
References
1.
LYMErix package literature. SmithKline Beecham Pharmaceuticals; December 1998.
2.
Centers for Disease Control and Prevention.Notice to readers on availability of Lyme disease vaccine. MMWR.1999; 48: 35–6, 43.
3.
HayesE.B., DennisD.T.Immunization against Lyme disease [letter]. N Engl J Med.1998; 339: 1637.
4.
FishD.Environmental risk and prevention of Lyme disease. Am J Med.1995; 98(suppl 4A): 2S–9S.
5.
SigalL.H.A vaccine consisting of recombinant Borrelia burgdorferi outersurface protein A to prevent Lyme disease. N Engl J Med.1998; 339: 216–22.
6.
Van HoeckeC.Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. Vaccine.1996; 14: 1620–6.
7.
Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases. Information on Lyme disease. June 1998. (www.cdc.gov/ncidod/dvbid/lymegen.htm)
8.
Centers for Disease Control and Prevention. Lyme disease—United States, 1996. MMWR.1997; 46: 531–5.
9.
Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1997. MMWR.1998; 47(54): 1–87.
10.
RahnD.W., FelzM.W.Lyme disease update. Current approach to early, disseminated, and late disease. Postgrad Med.1998; 103: 51–4, 57-9,63-4,70.
11.
Centers for Disease Control and Prevention.Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR.1995; 44: 590–1.
12.
HauplT.Activation of monocytes by three OspA vaccine candidates: Lipoprotein OspA is a potent stimulator of monokines. FEMS Immunol Med Microbiol.1997; 19: 15–23.
13.
de SilvaA.M.Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med.1996; 183: 271–5.
14.
WormserG.P.Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis.1995; 21: 1267–74.
15.
TelfordS.R.Efficacy of human Lyme disease vaccine formulations in a mouse model. J Infect Dis.1995; 171: 1368–70.
16.
PhilippM.T.The outer surface protein A (OspA) vaccine against Lyme disease: Efficacy in the rhesus monkey. Vaccine.1997; 15: 1872–87.
17.
GoldeW.T.Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun.1997; 65: 882–9.
18.
KurtenbachK.Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Vaccine.1997; 15: 1670–4.
19.
LukeC.J.An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis.1997; 175: 91–7.
20.
SteereA.C.Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med.1998; 339: 209–15.
21.
ParentiD.L.Evaluation of reacto-genicity and immunogenicity of LYMErix(J), recombination L. OspA vaccine against Lyme disease, administered on two different schedules [abstract]. Infectious Disease Society of America. Denver, CO; November 12-15, 1998; 705. (www.marathonmultimedia.com/scripts/abstracts/idsa)
22.
LeBacqE.A study to evaluate the reactogenicity and the immunogenicity of SmithKline Beecham Biologicals' vaccine against Lyme disease when administered on two different schedules [abstract]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA. September 24-27, 1998; G-90.
23.
TelfordS.Safety and immuno-genicity of a candidate Lyme disease (LD) vaccine in residents of endemic New England sites [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. September 17-20, 1995; G42.
24.
BeranJ.Evaluation of an OspA Lyme disease vaccine in children aged 5 to 15 years [abstract]. Infectious Disease Society of America. Denver, CO; November 12-15, 1998; 75. (www.marathonmul-timedia.com/scripts/abstracts/idsa)
25.
SchoenR.T.Safety and immuno-genicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis.1995; 172: 1324–9.
26.
KellerD.Safety and immuno-genicity of a recombinant outer surface protein A Lyme vaccine. JAMA.1994; 271: 1764–8.
27.
PadillaM.L.Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J Infect Dis.1996; 174: 739–46.
28.
GoldeW.T.The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Vaccine.1995; 13: 435–41.
29.
GernL.Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii. Vaccine.1997; 15: 1551–7.
30.
SteereS.C.Immunization against Lyme disease [letter]. N Engl J Med.1998; 339: 1638.
